Patents Represented by Attorney Gayle B. O'Brien
-
Patent number: 8217027Abstract: The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.Type: GrantFiled: March 11, 2008Date of Patent: July 10, 2012Assignee: Abbott LaboratoriesInventors: Grier A. Wallace, Eric C. Breinlinger, Kevin P. Cusack, Shannon R. Fix-Stenzel, Thomas D. Gordon, Adrian D. Hobson, Martin E. Hayes, Graham K. Ansell, Pintipa Grongsaard
-
Patent number: 8188083Abstract: The present invention is directed to novel compounds of formula (I) wherein the variables are defined as herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.Type: GrantFiled: June 26, 2008Date of Patent: May 29, 2012Assignee: Abbott LaboratoriesInventors: David J. Calderwood, Dominique F. Bonafoux, Andrew Burchat, Ping Ding, Kristine E. Frank, Michael Z. Hoemann, Kelly D. Mullen, Heather M. Davis
-
Patent number: 7956195Abstract: The present invention discloses processes for the preparation and isolation of the individual stereoisomers of 1-amino, 3-substituted phenylcyclopentane-carboxylates.Type: GrantFiled: December 21, 2007Date of Patent: June 7, 2011Assignee: Abbott LaboratoriesInventors: Thomas D. Gordon, Grier A. Wallace, Martin E. Hayes, Kirill A. Lukin, Lei Wang, Dilinie P. Fernando
-
Patent number: 7863444Abstract: Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disase states where angiogenesis or endothelial cell hyperproliferaton is a factor. These compounds can be used to treat cancer, hyperproliferative disorders, rheumatoid artheritis, disorders of the immune system, transplant rejection, and inflammatory disorders.Type: GrantFiled: September 17, 1999Date of Patent: January 4, 2011Assignee: Abbott LaboratoriesInventors: David Calderwood, Lee Arnold, Hormoz Mazdiyasni, Gavin C. Hirst, Bojuan B. Deng, David N. Johnston, Paul Rafferty, Gerald B. Tometzki, Helen L. Twigger, Rainer Munschauer
-
Patent number: 7834039Abstract: Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.Type: GrantFiled: December 14, 2007Date of Patent: November 16, 2010Assignee: Abbott LaboratoriesInventors: Adrian D. Hobson, Shannon R. Fix-Stenzel, Kevin P. Cusack, Eric C. Breinlinger, Graham K. Ansell, Robert H. Stoffel, Kevin R. Woller, Pintipa Grongsaard
-
Patent number: 7829570Abstract: The present application is directed to compounds of the formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.Type: GrantFiled: December 3, 2008Date of Patent: November 9, 2010Assignee: Abbott LaboratoriesInventors: Gavin C. Hirst, Andrew Burchat, Neil Wishart, David J. Calderwood, Michael R. Michaelides, Zhiqin Ji
-
Patent number: 7790741Abstract: The present invention is directed to novel compounds of formula (I) wherein the variables are as defined herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.Type: GrantFiled: October 5, 2007Date of Patent: September 7, 2010Assignee: Abbott LaboratoriesInventors: David J. Calderwood, Kristine E. Frank, David W. Borhani, Heather M. Davis, Nathan S. Josephsohn, Barbara S. Skinner
-
Patent number: 7049312Abstract: Q is —N=or CR2 X is S, O or NOR3 Y is —O—, —S—, —SO— or —SO2— R and R1 are each, independently, H, a substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aralkyl group R2 is H or a substituent R3 is H, or —C(O)R4 R4 is a substituted or unsubstituted aliphatic or aromatic group n is an integer from 0 to 1 Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.Type: GrantFiled: June 2, 2000Date of Patent: May 23, 2006Assignee: Abbott GmbH & Co. KGInventors: Paul Rafferty, David Calderwood, Lee Arnold, Beatriz Gonzalez Pascual, Jose L. Ortego Martinez, Maria J. Perez de Vega, Isabel Fernandez
-
Patent number: 6921763Abstract: The present invention is directed to pyrazolopyrimidine derivatives of formula (I) wherein the substituents are defined herein, which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.Type: GrantFiled: March 22, 2001Date of Patent: July 26, 2005Assignee: Abbott LaboratoriesInventors: Gavin C. Hirst, Paul Rafferty, Kurt Ritter, David Calderwood, Neil Wishart, Lee D. Arnold, Michael M. Friedman
-
Patent number: 6713474Abstract: Chemical compounds having structural formula I and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatiod arthritis, disorders of the immune system, trasplant rejections and imflammatory disorders.Type: GrantFiled: March 29, 2000Date of Patent: March 30, 2004Assignee: Abbott GmbH & Co. KGInventors: Gavin C. Hirst, David Calderwood, Rainer Munschauer, Lee D. Arnold, David N. Johnston, Paul Rafferty
-
Patent number: 6660744Abstract: The present invention is directed to pyrazolopyrimidine derivatives which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.Type: GrantFiled: September 15, 2000Date of Patent: December 9, 2003Assignee: Abbott GmbH & Co. KGInventors: Gavin C. Hirst, Paul Rafferty, Kurt Ritter, David Calderwood, Neil Wishart, Lee D. Arnold, Michael M. Friedman
-
Patent number: 6534655Abstract: Chemical compounds that are derivatives of indeno[1,2-c]pyrazole are inhibitors of tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell proliferation is a factor. Compounds of this invention also inhibit the induction of vascular hyperpermeability and the associated formation of edema, ascites, and exudates.Type: GrantFiled: April 3, 2000Date of Patent: March 18, 2003Assignee: BASF AktiengesellschaftInventors: Lee D. Arnold, Yajun Xu, Teresa Barlozzari, Paul Rafferty, Michael Hockley, Allyson Turner